Gene
FGF4
FGF4 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (2), Trial mentions (33), Target-disease associations (58), and 4 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FGF4. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 5 of 8,738 | 0.06% | not measured | |
| 2025 | 2 of 8,875 | 0.02% | not measured | |
| 2024 | 3 of 8,597 | 0.03% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 4 of 11,460 | 0.03% |
| 2022 | 1 of 8,285 | 0.01% | 8 of 13,598 | 0.06% |
| 2021 | 3 of 8,692 | 0.03% | 7 of 15,045 | 0.05% |
| 2020 | 5 of 7,640 | 0.07% | 3 of 14,459 | 0.02% |
| 2019 | 1 of 7,300 | 0.01% | 7 of 12,159 | 0.06% |
| 2018 | 1 of 6,927 | 0.01% | 4 of 11,854 | 0.03% |
| 2017 | 4 of 6,558 | 0.06% | 2 of 11,595 | 0.02% |
Showing 10 of 37 years.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FGF4 amplification | Lucitanib | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| FGF4 amplification | Dovitinib | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (33)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02699138 | Trial eligibility (AACT) |
| NCT03288376 | Trial eligibility (AACT) |
| NCT00185640 | Trial eligibility (AACT) |
| NCT04248192 | Trial eligibility (AACT) |
| NCT07417501 | Trial eligibility (AACT) |
Showing 5 of 33 trial mentions.
Target-disease associations (58)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of the liver | phenotype | GWAS credible sets |
| Autoimmune Hepatitis | endocrine system disease | Literature (Europe PMC) |
| C-C motif chemokine 3-like 1 measurement | measurement | GWAS credible sets |
| COVID-19–associated multisystem inflammatory syndrome in adults | infectious disease | Literature (Europe PMC) |
| Down syndrome | genetic, familial or congenital disease | Expression Atlas |
Showing 5 of 58 associations.
Vendor sourcing (104)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.480T>G (p.I160M) alteration is located in exon 3 (coding exon 3) of the FGF4 gene. This alteration results from a T to G substitution at nucleotide pos... | View ClinVar record SCV003536786.3 |
| Amenity Health, Inc. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Diagnosis with mild obstructive sleep apnea (AHI 5-14.9) 2. PSG or HST performed within last 24 months 3. Individuals aged 18 or older 4. Must routinel... | View trial NCT07492420 |
| Amenity Health, Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | HST | View trial NCT07492420 |
| Andrea Romigi | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : • Consecutive symptomatic OSAS patients with an AHI and an oxygen desaturation index (ODI) of \>15/h in polysomnography (PSG) or Home Sleep Test (HST) cons... | View trial NCT04300166 |
| Andrea Romigi | Trial sponsor | Mentioned in trial textTrial free-text mention | HST | View trial NCT04300166 |
Showing 5 of 104 sourcing records.
Trial-cited literature (79)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Innovative biomaterials in promoting intraoral wound healing: Mechanisms, applications, and challenges. | Materials today. Bio | 2025 | 7 |
| A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | 21 |
| Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial. | BMC medicine | 2023 | 20 |
| First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. | Targeted oncology | 2023 | 7 |
| Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial. | Investigational new drugs | 2023 | 4 |
Showing 5 of 79 papers.
Literature-extracted relations (4)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. | 2015 |
| Angina Pectoris | Disease | associate |
Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. | 2002 |
| Brain Ischemia | Disease | inhibit |
Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. | 2002 |
| Fever | Disease | stimulate |
Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. | 2002 |
Organizations publishing (104)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Harvard Medical School | Academic | 4 | 2019 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 3 | 2015 to 2023 |
| Roche (Switzerland) | Industry | 3 | 2015 to 2023 |
| The University of Texas System | Academic | 3 | 2021 to 2022 |
| Asan Foundation | Nonprofit | 2 | 2019 to 2021 |
Showing 5 of 104 organizations.
Where FGF4 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
57 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, protein variant mentions, and human sample screening reference.